Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation: London, UK Saturday, August 9, 2025, 10:00 Hrs [IST] GSK plc announces that, in connection with th ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

GSK is set to receive up to $500 million and 1% royalties on future vaccine sales following the settlement of a US patent dispute between CureVac NV, Pfizer, and BioNTech SE.

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

Flutter Entertainment (FLTR) upped full-year guidance after a solid second quarter, with group revenue up 16 per cent to $4.2bn (£3.1bn) and adjusted Ebitda climbing 25 per cent to $919mn. Average ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.